|Bid||5.53 x 4000|
|Ask||5.54 x 1800|
|Day's Range||5.50 - 5.60|
|52 Week Range||4.49 - 8.05|
|Beta (3Y Monthly)||1.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 5, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
While small-cap stocks, such as Cerus Corporation (NASDAQ:CERS) with its market cap of US$744m, are popular for their...
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
Cerus Corporation announced today that multiple abstracts featuring the INTERCEPT Blood System pathogen reduction technology, including four oral presentations, will be included in the scientific program at the 29th regional congress of International Society of Blood Transfusion .
Anyone researching Cerus Corporation (NASDAQ:CERS) might want to consider the historical volatility of the share...
Cerus Corporation (CERS) announced today a new corporate branding campaign building upon the Company’s leadership position in helping to safeguard the world’s blood supply and the planned relocation of its corporate offices to a new facility in Concord California. The new corporate brand reflects Cerus’ increasingly important role in helping blood centers globally to proactively protect the blood supply against the threat of known and emerging infectious diseases. The Company aims to be the global leader in pathogen reduction technologies and a trusted partner of blood centers and hospitals.
Cerus Corporation (CERS) today announced that the FDA has issued a final guidance document recommending protocols for reducing the risk of transfusion transmitted Babesiosis. In 15 Babesiosis endemic states, treating donated blood components with the INTERCEPT Blood System is a recognized alternative to year-round Babesia testing using a DNA-based test. “We are pleased that treating donated blood components with a pathogen-reduction technology such as INTERCEPT was selected as one of the two options recognized by the FDA to reduce the risk of transfusion transmitted Babesiosis,” said Dr. Richard Benjamin, Cerus’ chief medical officer.
Cerus (CERS) delivered earnings and revenue surprises of -16.67% and 11.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Concord, California-based company said it had a loss of 14 cents. The biomedical products company posted revenue of $17.5 million in the period. Cerus expects full-year revenue ...
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So we'll take a look at...
Cerus Corporation (CERS) today announced the closing of a new debt facility with MidCap Financial (MidCap) which is expandable up to $90 million. The debt facility consists of a staged $70 million term loan and a $5 million revolving line of credit, expandable up to $20 million. The new term loan provides an initial tranche of $40 million at closing.
Cerus Corporation (CERS) today announced the appointment of Jami Nachtsheim to its Board of Directors. Ms. Nachtsheim currently serves on the Board at Intuitive Surgical, the global market leader in robotic-assisted minimally invasive surgical systems. Ms. Nachtsheim brings nearly four decades of commercial and marketing leadership experience to the Cerus Board.
Cerus Corporation today announced complete financial results for the fourth quarter and year ended December 31, 2018.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The big shareholder groups in Cerus Corporation (NASDAQ:CERS) have powerRead More...
NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Cerus Corporation announced today that its fourth quarter and full-year 2018 results will be released on Tuesday, February 26, 2019, after the close of the stock market.
In 2011 Obi Greenman was appointed CEO of Cerus Corporation (NASDAQ:CERS). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Read More...